Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052780" target="_blank" >RIV/00216224:14110/11:00052780 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—

Jazyk výsledku
angličtina
Název v původním jazyce
Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval
Popis výsledku v původním jazyce
Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non smallcell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients.
Název v anglickém jazyce
Oral vinorelbin in combination with cisplatin or carboplatin in adjutant chemotherapy of non-snall lung cancer: A prospective study of feasibility, tolerabity an 3-year surfoval
Popis výsledku anglicky
Adjuvant cisplatinum-based chemotherapy is recommended for routine use in patients with stages IIA, IIB, and IIIA of non smallcell lung cancer (NSCLC) after radical resection. Results in stage IB were not conclusive. Vinorelbine is a preferable associated drug in this indication and a randomized study proved the comparable effectiveness and tolerability of vinorelbine given both orally or intravenously (i.v.) in advanced NSCLC, meanwhile oral vinorelbine gives better comfort to patients.

Rok uplatnění
2011
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)